BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24789441)

  • 1. Role of CIP2A in the antitumor effect of bortezomib in colon cancer.
    Ding Y; Wang Y; Ju S; Wu X; Zhu W; Shi F; Mao L
    Mol Med Rep; 2014 Jul; 10(1):387-92. PubMed ID: 24789441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
    Chen KF; Liu CY; Lin YC; Yu HC; Liu TH; Hou DR; Chen PJ; Cheng AL
    Oncogene; 2010 Nov; 29(47):6257-66. PubMed ID: 20729919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
    Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A.
    Chen KF; Yu HC; Liu CY; Chen HJ; Chen YC; Hou DR; Chen PJ; Cheng AL
    Mol Cancer Ther; 2011 May; 10(5):892-901. PubMed ID: 21393428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A.
    Huang CY; Wei CC; Chen KC; Chen HJ; Cheng AL; Chen KF
    Cancer Lett; 2012 Apr; 317(1):9-15. PubMed ID: 22085493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC; Chen KC; Chen CC; Cheng AL; Chen KF
    Oral Oncol; 2012 Jul; 48(7):585-93. PubMed ID: 22342571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
    Liu CY; Shiau CW; Kuo HY; Huang HP; Chen MH; Tzeng CH; Chen KF
    Haematologica; 2013 May; 98(5):729-38. PubMed ID: 22983581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition.
    Hou DR; Huang AC; Shiau CW; Wang CY; Yu HC; Chen KF
    Molecules; 2013 Dec; 18(12):15398-411. PubMed ID: 24335617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
    Gao F; Wang X; Chen S; Xu T; Wang X; Shen Y; Dong F; Zhong S; Shen Z
    Oncol Rep; 2018 Nov; 40(5):2445-2454. PubMed ID: 30106121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism.
    Wang HW; Yang SH; Huang GD; Lin JK; Chen WS; Jiang JK; Lan YT; Lin CC; Hwang WL; Tzeng CH; Li AF; Yen CC; Teng HW
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):561-71. PubMed ID: 24493623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
    Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
    Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.
    Yu HC; Hou DR; Liu CY; Lin CS; Shiau CW; Cheng AL; Chen KF
    PLoS One; 2013; 8(2):e55705. PubMed ID: 23383345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
    Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
    Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells.
    Liu CY; Huang TT; Huang CT; Hu MH; Wang DS; Wang WL; Tsai WC; Lee CH; Lau KY; Yang HP; Chen MH; Shiau CW; Tseng LM; Chen KF
    Eur J Cancer; 2017 Feb; 72():112-123. PubMed ID: 28027514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CIP2A is a predictor of poor prognosis in colon cancer.
    Teng HW; Yang SH; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Chen PC; Lan YT; Lin CC; Hsu YN; Wang HW; Chen KF
    J Gastrointest Surg; 2012 May; 16(5):1037-47. PubMed ID: 22328001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells.
    Kao C; Chao A; Tsai CL; Lin CY; Chuang WC; Chen HW; Yen TC; Wang TH; Lai CH; Wang HS
    Cell Death Dis; 2013 Feb; 4(2):e512. PubMed ID: 23449448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells.
    Zhao Q; Zhao M; Parris AB; Xing Y; Yang X
    Int J Oncol; 2016 Sep; 49(3):1203-10. PubMed ID: 27574003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
    Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
    Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis.
    Dong QZ; Wang Y; Dong XJ; Li ZX; Tang ZP; Cui QZ; Wang EH
    Ann Surg Oncol; 2011 Mar; 18(3):857-65. PubMed ID: 20842459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression.
    Wiegering A; Pfann C; Uthe FW; Otto C; Rycak L; Mäder U; Gasser M; Waaga-Gasser AM; Eilers M; Germer CT
    PLoS One; 2013; 8(10):e75292. PubMed ID: 24098375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.